Tag: vascular trauma
US FDA approves Humacyte’s Symvess for vascular trauma
Humacyte recently shared that the US Food and Drug Administration (FDA) has granted a full approval for the Symvess acellular tissue-engineered vessel.
A press release...
REBOA: Is balloon use in emergency trauma really just hot air?
Balloon occlusion is one of the most hotly contested topics when it comes to vascular surgery in the setting of emergency trauma and, with...
Human Acellular Vessel Biologics License Application granted priority review by US...
Humacyte has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review to Humacyte’s Biologics License Application (BLA) seeking...
MVSS 2023: Human Acellular Vessel proves ‘safe, effective bypass conduit’ in...
An investigator-sponsored clinical study conducted at the Mayo Clinic in Rochester, Minnesota, of the investigational Human Acellular Vessel (HAV) in patients with chronic limb-threatening...
Humacyte announces positive top line results from Phase 2/3 trial of...
Humacyte has announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair.
A...
Clinical performance of Human Acellular Vessel amid war in Ukraine presented...
Clinical outcomes of Humacyte's investigational Human Acellular Vessel (HAV) were presented at the recent Military Health System Research Symposium (14–17 August, Kissimmee, USA), following...
Human-tissue engineered blood vessels remain durable at six years in PAD...
Mid-term results from a phase II study of surgical bypass using the Human Acellular Vessel (HAV; Humacyte) demonstrated an overall secondary patency rate at...
Systemic heparin during TEVAR deemed safe for selected traumatic brain injury...
The use of systemic heparin during thoracic endovascular aneurysm repair (TEVAR) for blunt thoracic aortic injuries (BTAI) appears to be safe in selected patients...
Humacyte provides update on patients treated at front-line hospitals in Ukraine...
Humacyte today announced that the first Ukrainian patients have received implants of the Human Acellular Vessel (HAV) for the treatment of vascular trauma injuries....
CX returns to in-person format once more in the London spring
Charing Cross (CX) chair Roger Greenhalgh welcomes the vascular community to this year's symposium, due to be held 26–28 April in London, UK, and...
Study indicates increasing vascular surgeon involvement in trauma cases
Fifteen years’ worth of data from a major US trauma centre suggest that the involvement of vascular surgeons in trauma management has increased over...
Endovascular resuscitation and trauma management: Vascular surgeons and interventionalists should take...
In the last 20 years, there have been major developments in the use of endovascular and hybrid haemorrhage control tools, especially in the treatment...
Humacyte commences phase II vascular trauma trial
Humacyte has announced the initiation of a US phase II vascular trauma clinical trial of Humacyl, its investigational human acellular vessel, for vascular replacement...
